COMP <GO>
OCS vs CTMX // FREE CASH FLOW YIELD
Oculis Holding AG (NASDAQ) VS. CytomX Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: OCS 1
— CTMX 1
■ METRIC PARITY
LAST: $7.71 (-6.66%) • MKT CAP: $508.7M
fcf-yield
—
LAST: $2.23 (-4.70%) • MKT CAP: $509.9M
fcf-yield
-15.19%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OCS VS. CTMX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OCS | CTMX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -20.50% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | — | -15.19% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -29.30% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -22.80% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -44.80% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 1/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 43.5 | +2.20 | OCS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $508.7M | $509.9M | -$1.2M | CTMX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OCS REV | CTMX REV | OCS GROSS % | CTMX GROSS % | OCS FCF | CTMX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $76.2M | — | — | — | -$75.8M |
| FY 2024 | — | $138.1M | — | — | — | -$86.5M |
| FY 2023 | — | $101.2M | — | — | — | -$56.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OCS // BETA —
CTMX // BETA —